Telix Pharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Feb 20, 2026 and accepted by EDGAR at Feb 19, 2026, 20:44 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $803.8m | ifrs-full:Revenue |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $377.4m | ifrs-full:CostOfSales |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $426.4m | ifrs-full:GrossProfit |
| Operating income | 12 months2025-01-01 to 2025-12-31 | $29.8m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $1.9m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$7.1m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$0.02 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$0.02 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$17.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $25.7m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2025-12-31 | $141.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2025-12-31 | $330.3m | ifrs-full:CurrentAssets |
| Total assets | At period end2025-12-31 | $1.16bn | ifrs-full:Assets |
| Current liabilities | At period end2025-12-31 | $231.6m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2025-12-31 | $748.6m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $415.4m | ifrs-full:Equity |
| Shares outstanding | At period end2025-12-31 | 338,777,049 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001628280-26-009943. Last ingested by Listed: Oct 29, 2026, 16:54 ET. Listed shows no prices and gives no investment advice.